Camber Capital Management’s NuVasive, Inc. NUVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-600,000
Closed -$24.8M 43
2023
Q1
$24.8M Buy
600,000
+100,000
+20% +$4.28M 0.76% 26
2022
Q4
$20.6M Hold
500,000
0.71% 28
2022
Q3
$21.9M Hold
500,000
0.67% 33
2022
Q2
$24.6M Hold
500,000
1.07% 24
2022
Q1
$28.4M Buy
500,000
+400,000
+400% +$21.2M 1.03% 24
2021
Q4
$5.25M Buy
+100,000
New +$5.44M 0.18% 36
2020
Q2
Sell
-33,630
Closed -$1.7M 38
2020
Q1
$1.7M Buy
+33,630
New +$2.25M 0.1% 29
2019
Q2
Sell
-750,000
Closed -$42.6M 34
2019
Q1
$42.6M Buy
+750,000
New +$39.9M 2.12% 20
2018
Q3
Sell
-1,200,000
Closed -$62.5M 29
2018
Q2
$62.5M Hold
1,200,000
2.41% 18
2018
Q1
$62.7M Buy
+1,200,000
New +$60.9M 3.08% 14
2016
Q3
Sell
-750,000
Closed -$44.8M 44
2016
Q2
$44.8M Sell
750,000
-750,000
-50% -$40.5M 2.16% 21
2016
Q1
$73M Buy
1,500,000
+400,000
+36% +$18.2M 4.27% 5
2015
Q4
$59.5M Hold
1,100,000
3.85% 9
2015
Q3
$53M Hold
1,100,000
4.54% 6
2015
Q2
$52.1M Buy
+1,100,000
New +$51.4M 3.55% 12

Other funds holding NUVA

Camber Capital Management's NUVA Position: Q2 2023 in Review

Camber Capital Management sold out of NuVasive, Inc. (NUVA) in Q2 2023, closing a stake of 600,000 shares — an estimated $24.8M sold.

Camber Capital Management first reported a position in NUVA in Q2 2015 and held it in 15 quarters. The position peaked at $73M in Q1 2016. 228 funds tracked by Wall St. Rank hold NUVA as of Q2 2023.

  • Camber Capital Management reported no remaining NuVasive, Inc. position as of Q2 2023 after selling out during the quarter.
  • Camber Capital Management sold 600,000 NuVasive, Inc. shares in Q2 2023, an estimated $24.8M.
  • Camber Capital Management first reported a position in NuVasive, Inc. in Q2 2015 and held it in 15 quarters.
  • Camber Capital Management's NuVasive, Inc. position peaked at $73M in Q1 2016.
  • 228 funds tracked by Wall St. Rank held NuVasive, Inc. as of Q2 2023.

Based on Camber Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.